» Articles » PMID: 31222503

Endothelial or Vascular Smooth Muscle Cell-specific Expression of Human NOX5 Exacerbates Renal Inflammation, Fibrosis and Albuminuria in the Akita Mouse

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2019 Jun 22
PMID 31222503
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/hypothesis: Excessive production of reactive oxygen species (ROS) plays a detrimental role in the progression of diabetic kidney disease (DKD). Renal oxidative stress activates proinflammatory cytokines, chemokines and profibrotic factors in DKD. Increased expression of the prooxidant enzyme NADPH oxidase (NOX) 5 in kidneys of diabetic individuals has been hypothesised to correlate with renal injury and progression of DKD. Since the gene encoding NOX5 is not expressed in the mouse genome, we examined the effect of inducible human NOX5 expression in renal cells, selectively in either endothelial cells or vascular smooth muscle cells (VSMCs)/mesangial cells in a model of insulin-deficient diabetes, the Akita mouse.

Methods: Renal structural injury, including glomerulosclerosis, mesangial expansion and extracellular matrix protein accumulation, as well as renal inflammation, ROS formation and albuminuria, were examined in the NOX5 transgenic Akita mouse model of DKD.

Results: Expression of NOX5 in either endothelial cells or VSMCs/mesangial cells in diabetic Akita mice was associated with increased renal inflammation (monocyte chemoattractant protein-1, NF-κB and toll-like receptor-4) and glomerulosclerosis, as well as upregulation of protein kinase C-α and increased expression of extracellular matrix genes (encoding collagen III, fibronectin and α-smooth muscle actin) and proteins (collagen IV), most likely mediated via enhanced renal ROS production. The effect of VSMC/mesangial cell-specific NOX5 expression resulted in more pronounced renal fibrosis in comparison with endothelial cell-specific NOX5 expression in diabetic mice. In addition, albuminuria was significantly increased in diabetic VEcadNOX5 mice (1192 ± 194 μg/24 h) when compared with diabetic VEcadNOX5 mice (770 ± 98 μg/24 h). Furthermore, the regulatory components of NOX5 activation, including heat shock protein 90 and transient receptor potential cation channel subfamily C member 6, were upregulated only in the presence of both NOX5 and diabetes.

Conclusions/interpretation: The findings from this study highlight the importance of NOX5 in promoting diabetes-related renal injury and provide the rationale for the development of a selective NOX5 inhibitor for the prevention and/or treatment of DKD.

Citing Articles

Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies.

Karakasis P, Theofilis P, Patoulias D, Vlachakis P, Antoniadis A, Fragakis N Int J Mol Sci. 2025; 26(5).

PMID: 40076813 PMC: 11900163. DOI: 10.3390/ijms26052196.


Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches.

Khan A, Jandeleit-Dahm K Nat Rev Cardiol. 2025; .

PMID: 39805949 DOI: 10.1038/s41569-024-01115-w.


Oxidative Stress in Kidney Injury and Hypertension.

Arendshorst W, Vendrov A, Kumar N, Ganesh S, Madamanchi N Antioxidants (Basel). 2025; 13(12.

PMID: 39765782 PMC: 11672783. DOI: 10.3390/antiox13121454.


Associations between non-insulin-based insulin resistance indices and diabetic nephropathy in patients with diabetes mellitus in US adults: a cross-sectional study of NHANES 1999-2018.

Zhang F, Han Y, Mao Y, Li W Front Endocrinol (Lausanne). 2024; 15:1458521.

PMID: 39720248 PMC: 11666371. DOI: 10.3389/fendo.2024.1458521.


NADPH Oxidase 5 (NOX5) Upregulates MMP-10 Production and Cell Migration in Human Endothelial Cells.

Marques J, Ainzua E, Orbe J, Martinez-Azcona M, Martinez-Gonzalez J, Zalba G Antioxidants (Basel). 2024; 13(10).

PMID: 39456453 PMC: 11504164. DOI: 10.3390/antiox13101199.


References
1.
He X, Kan H, Cai L, Ma Q . Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J Mol Cell Cardiol. 2008; 46(1):47-58. DOI: 10.1016/j.yjmcc.2008.10.007. View

2.
Molitch M, DeFronzo R, Franz M, Keane W, Mogensen C, Parving H . Nephropathy in diabetes. Diabetes Care. 2003; 27 Suppl 1:S79-83. DOI: 10.2337/diacare.27.2007.s79. View

3.
Watson A, Li J, Schumacher C, de Gasparo M, Feng B, Thomas M . The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia. 2009; 53(1):192-203. DOI: 10.1007/s00125-009-1540-3. View

4.
Cheng X, Siow R, Mann G . Impaired redox signaling and antioxidant gene expression in endothelial cells in diabetes: a role for mitochondria and the nuclear factor-E2-related factor 2-Kelch-like ECH-associated protein 1 defense pathway. Antioxid Redox Signal. 2010; 14(3):469-87. DOI: 10.1089/ars.2010.3283. View

5.
Jha J, Thallas-Bonke V, Banal C, Gray S, Chow B, Ramm G . Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy. Diabetologia. 2015; 59(2):379-89. PMC: 6450410. DOI: 10.1007/s00125-015-3796-0. View